Skip to content

Clinical evaluation and mechanistic research of reinforcing the kidney and eliminating wet combined with platelet-rich plasma in the treatment of earlier period of knee oseoarthritis.

Clinical evaluation and mechanistic research of reinforcing the kidney and eliminating wet combined with platelet-rich plasma in the treatment of earlier period of knee oseoarthritis.

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000038502
Enrollment
Unknown
Registered
2020-09-23
Start date
2020-11-01
Completion date
Unknown
Last updated
2020-11-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Early osteoarthritis of the knee

Interventions

Sponsors

Wangjing Hospital, China Academy of Chinese Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
38 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Meet the diagnostic criteria of western or Traditional Chinese medicine for knee osteoarthritis; 2. It meets the requirements for the indications of the diagnosis and treatment technology studied; 3. Compliance with Kellgren-lawrance X-ray classification level 0, Level I and Level II; 4. Sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients who do not meet the diagnostic criteria and inclusion criteria for knee osteoarthritis. 2. Those who have received other relevant treatments, which may affect the effect indicators in this study. 3. Patients with life-threatening primary diseases such as cardiovascular and cerebrovascular diseases, liver and kidney diseases and mental diseases. 4. Exclude research diseases: (1) rheumatic diseases: rheumatoid arthritis, ankylosing spondylitis, etc.; (2) Infectious arthritis: joint tuberculosis, purulent arthritis, etc.; (3) Reactive arthritis: allergic arthritis, thrombocytopenic purpura arthritis; (4) Metabolic joint diseases: Kashin-beck disease, gout, etc.; (5) Intra-articular tumor; (6) Other specific joint diseases.

Design outcomes

Primary

MeasureTime frame
WOMAC Osteoarthritis Index score;Lequesne index score;TCM clinical symptom score;Serum indexes (TGF-beta 1, BMP-2, Smad1);

Countries

China

Contacts

Public ContactHongmei Zhang

Wangjing Hospital

wangjingzhm@sina.com+86 010-84739145

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026